Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens

Published:2020-02-28 Issue:2 Volume:3 Page:e200202
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Parikh Kaushal¹²,Huether Robert³,White Kevin³,Hoskinson Derick³,Beaubier Nike³,Dong Haidong⁴,Adjei Alex A.¹,Mansfield Aaron S.¹

Affiliation:

1. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota

2. Division of Medical Oncology, John Theurer Cancer Center, Hackensack, New Jersey

3. Tempus Labs, Chicago, Illinois

4. Department of Urology, Department of Immunology, Mayo Clinic, Rochester, Minnesota

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2762022/parikh_2020_oi_200019.pdf

Reference16 articles.

1. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.;Mansfield;Ann Oncol,2016

2. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.;Goodman;Mol Cancer Ther,2017

3. Neoantigens in cancer immunotherapy.;Schumacher;Science,2015

4. Integrated genomic profiling expands clinical options for patients with cancer.;Beaubier;Nat Biotechnol,2019

5. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.;Beaubier;Oncotarget,2019

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma;Journal of Personalized Medicine;2024-09-08

2. Recommendations for Tumor Mutational Burden Assay Validation and Reporting;The Journal of Molecular Diagnostics;2024-08

3. Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test;Cancer Investigation;2024-05-21

4. A Deep Multi-Omics Integration Approach Reveals New Molecular Features of Uterine Leiomyosarcoma;2024-04-26

5. Incorporating Real-World Clinico-Genomic Insights to Inform Diversity Enrollment Targets in Oncology Trials;2024-04-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3